Frauenklinik, Inselspital Bern, University of Bern, Switzerland.
Eur J Obstet Gynecol Reprod Biol. 2023 Aug;287:171-175. doi: 10.1016/j.ejogrb.2023.06.003. Epub 2023 Jun 8.
Aim of our study was to evaluate the therapeutic effect of laser treatment in vulvar lichen sclerosus, mainly the reduction of existing symptoms as itching, burning and pain. We asked about the different outcome by using different application doses.
We conducted a prospective randomized double-blind dose-controlled trial in our dysplasia unit specializing vulvar disorders. 67patients with active LS were included. LS was confirmed by biopsy or by the validated CSS (clinical scoring system of vulvar LS). Computer generated randomization resulted in two groups, each group received a different application dose.(LDG- low dose group, NDG- normal dose group) During the study period of 18 weeks all participants received three laser applications in three subsequent sessions of three weeks. Two follow-ups six and twelve weeks after the first application was performed. At every visit, the participants filled in the VAS (visual analogue scale) for recording the actual vulvar symptoms as itching burning or pain on a range from 0 to 10.
Before treatment the mean VAS-Score was 4.3 (STD ± 2.4) in the NDG and 5.1(±2.6) in the LDG. After 18 weeks, the mean reduction was -2.4 (±2.3) for NDG and -2.7 (±2.8) for LDG. Four patients (two of each group) reported more pain after than before treatment. Both groups show significant lower VAS-Scores 18 weeks after the treatment than before therapy (p < 0.0001). The reduction of symptoms after 18 weeks between NDG and LDG was not significant (p = 0.6244).
Laser treatment with the microablative CO2 laser leads to a significant improvement for symptoms of LS. A higher dosage of laser radiation shows no benefit concerning the symptoms. We have not observed any serious adverse events during this study.
本研究旨在评估激光治疗外阴硬化性苔藓(lichen sclerosus,LS)的疗效,主要观察瘙痒、灼热和疼痛等现有症状的缓解情况。我们通过不同的应用剂量观察不同的结果。
我们在专门治疗外阴疾病的发育不良科进行了一项前瞻性随机双盲剂量对照试验。纳入 67 例活动性 LS 患者。LS 通过活检或经过验证的 CSS(外阴 LS 临床评分系统)确诊。计算机生成的随机分组导致两组患者分别接受不同的应用剂量(LDG-低剂量组,NDG-正常剂量组)。在 18 周的研究期间,所有参与者接受三次激光治疗,三次治疗之间间隔 3 周。在第一次治疗后 6 周和 12 周进行两次随访。每次就诊时,参与者使用视觉模拟量表(VAS)记录实际的外阴症状,瘙痒、灼热或疼痛的程度范围为 0 至 10。
治疗前,NDG 的平均 VAS 评分为 4.3(STD±2.4),LDG 的平均 VAS 评分为 5.1(±2.6)。治疗 18 周后,NDG 的平均降幅为-2.4(±2.3),LDG 的平均降幅为-2.7(±2.8)。有 4 名患者(每组各 2 名)在治疗后报告的疼痛比治疗前更严重。两组患者在治疗后 18 周的 VAS 评分均显著低于治疗前(p<0.0001)。治疗 18 周后,NDG 和 LDG 之间症状的缓解差异无统计学意义(p=0.6244)。
采用微剥脱 CO2 激光治疗可显著改善 LS 症状。更高剂量的激光辐射对症状并无益处。在本研究中未观察到任何严重不良事件。